Entity

Time filter

Source Type


Zhang H.-L.,Central Hospital of Zhumadian City | Zhang Y.-J.,Zhengzhou University
Tumor Biology | Year: 2013

Tumor necrosis factor alpha (TNF-α) is a multifunctional cytokine which plays an important role in the human immune response against various pathogens, and there may be a relationship between TNF-α 308 G/A polymorphism and cervical cancer risk. We performed a meta-analysis to get a systemic assessment of the association between TNF-α 308 G/A polymorphism and cervical cancer risk. Electronic searches of PubMed, Embase, and Web of Science were performed for all publications on the association between TNF-α 308 G/A polymorphism and cervical cancer risk through October 26, 2012. The pooled odds ratios (ORs) with their 95 % confidence interval (95 % CIs) were calculated to assess the association. Fifteen studies with a total of 3,743 cervical cancer cases and 4,096 controls were finally included into the meta-analysis. Overall, TNF-α 308 G/A polymorphism was significantly associated with increased risk of cervical cancer under three main genetic comparison models (A vs. G, OR 1.20, 95 % CI 1.02-1.42, P = 0.03; AA vs. GG, OR 1.31, 95 % CI 1.00-1.72, P = 0.048; AA vs. GG/GA, OR 1.30, 95 % CI 1.00-1.71, P = 0.05). Subgroup analysis by ethnicity further showed that there was a significant association between TNF-α 308 G/A polymorphism and increased risk of cervical cancer in Asians (AA vs. GG, OR 1.83, 95 % CI 1.05-3.20, P = 0.034; AA vs. GG/GA, OR 1.84, 95 % CI 1.05-3.22, P = 0.032). The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with increased risk of cervical cancer, and TNF-α 308 G/A mutant allele A is a risk factor of cervical cancer. © 2013 International Society of Oncology and BioMarkers (ISOBM).


Zhang H.,Central Hospital of Zhumadian City | Zhang H.,Huanghuai University | Wen X.,Central Hospital of Zhumadian City | Lu X.,Central Hospital of Zhumadian City
Tumor Biology | Year: 2013

NAD(P)H:quinone oxidoreductase 1 (NQO1) rs1800566 (Pro187Ser) is a functional polymorphism which leads to a proline-to-serine amino acid substitution at codon 187 in the NQO1 protein and enzyme activity changes. NQO1 rs1800566 polymorphism was implicated to be associated with a risk of bladder cancer, but published studies showed inconclusive results. We performed a meta-analysis of nine publications with a total of 2,661 cases and 2,738 controls on the association between NQO1 rs1800566 polymorphism and risk of bladder cancer. Data were extracted from those included studies, and the pooled odds ratio (OR) with the corresponding 95 % confidence interval (95 % CI) was calculated to assess the association. We found that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.06, 95 % CI = 0.97-1.16, P = 0.21, I 2 = 31 %; SerSer vs. ProPro, OR = 1.12, 95 % CI = 0.89-1.42, P = 0.33, I 2 = 44 %; SerSer/ProSer vs. ProPro, OR = 1.08, 95 % CI = 0.96-1.21, P = 0.20, I 2 = 27 %; SerSer vs. ProPro/ProSer, OR = 1.06, 95 % CI = 0.85-1.32, P = 0.59, I 2 = 36 %). Meta-analysis of those eight studies from Europeans also showed that there was no association between NQO1 rs1800566 polymorphism and risk of bladder cancer under all four genetic models (Ser vs. Pro, OR = 1.02, 95 % CI = 0.93-1.13, P = 0.66, I 2 = 20 %; SerSer vs. ProPro, OR = 0.99, 95 % CI = 0.75-1.30, P = 0.93, I 2 = 38 %; SerSer/ProSer vs. ProPro, OR = 1.04, 95 % CI = 0.92-1.17, P = 0.55, I 2 = 6 %; SerSer vs. ProPro/ProSer, OR = 0.98, 95 % CI = 0.75-1.28, P = 0.87, I 2 = 39 %). This meta-analysis suggests that the NQO1 rs1800566 polymorphism is not associated with a risk of bladder cancer. Further studies with larger samples are needed, especially for studies in Asians and Africans. © 2013 International Society of Oncology and BioMarkers (ISOBM).


Zhang H.,Central Hospital of Zhumadian City | Zhang H.,Huanghuai College | Wen X.,Central Hospital of Zhumadian City | Zhang Y.,Central Hospital of Zhumadian City | And 2 more authors.
Cellular Physiology and Biochemistry | Year: 2015

Background/Aims: Vitamin D status in relation to bladder carcinoma risk was still inconsistent. This study was carried out to evaluate the relationship between vitamin D status and bladder carcinoma risk through a meta-analysis approach. Methods: Pubmed, Web of Science, CNKI, and Embase were searched systemically to find eligible studies from the earliest available date to April 16, 2015. The search terms "vitamin D", "25-hydroxyvitamin D", "bladder cancer" or "bladder carcinoma" were used to retrieve relevant studies. The exposure of interest was intake of vitamin D or serum vitamin D levels, and the outcome of interest was bladder carcinoma incidence or mortality. The pooled risk ratio (RR) values and their 95%CIs were calculated through meta-analysis. Results: Seven studies with a total of 62,141 participants met the inclusion criteria and were finally included into the meta-analysis. There was no heterogeneity among those included studies (I2 = 0%, P = 0.53). The pooled RR of bladder carcinoma for the lowest category versus the highest category of vitamin D was 1.34 (95% CI 1.17-1.53, P < 0.0001). Sensitivity analysis by omitting one study by turns showed all the pooled RRs were statistically significant. Meta-analysis of 5 studies reporting outcomes of serum vitamin D levels also showed that the low serum vitamin D level was associated with increased risk of bladder carcinoma (RR = 1.32, 95%CI 1.15-1.52, P = 0.0001). No obvious risk of publication bias was observed. Conclusion: Vitamin D deficiency is associated with increased risk of bladder carcinoma in present study. © 2015 S. Karger AG, Basel.

Discover hidden collaborations